AbCellera Biologics Inc (NASDAQ:ABCL) Up 21.79% Over A Week, Now Can The Stock Hit Well Above $0.68?

In last trading session, AbCellera Biologics Inc (NASDAQ:ABCL) saw 9.92 million shares changing hands with its beta currently measuring 0.52. Company’s recent per share price level of $3.8 trading at $0.12 or 3.26% at ring of the bell on the day assigns it a market valuation of $1.13B. That closing price of ABCL’s stock is at a premium of 0.79% from its 52-week high price of $3.77 and is indicating a premium of 50.26% from its 52-week low price of $1.89.

For AbCellera Biologics Inc (ABCL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Upright in the green during last session for gaining 3.26%, in the last five days ABCL remained trading in the green while hitting it’s week-highest on Wednesday, 06/25/25 when the stock touched $3.8 price level, adding 7.09% to its value on the day. AbCellera Biologics Inc’s shares saw a change of 31.03% in year-to-date performance and have moved 21.79% in past 5-day. AbCellera Biologics Inc (NASDAQ:ABCL) showed a performance of 92.89% in past 30-days.

Wall Street analysts have assigned a consensus price target of 23.5 to the stock, which implies a rise of 83.83% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 34. It follows that stock’s current price would drop -31.58% in reaching the projected high whereas dropping to the targeted low would mean a loss of -31.58% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -107.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -10.77% while estimates for its earnings growth in next 5 years are of 0.83%.

AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders

BAKER BROS. ADVISORS LP is the top institutional holder at ABCL for having 27.53 million shares of worth $81.48 million. And as of 2024-06-30, it was holding 9.3556 of the company’s outstanding shares.

The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 21.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4472 of outstanding shares, having a total worth of $64.86 million.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.